// App-Quantinova.ai

OP0241 (2021) : SERIOUS INFECTION WITH TOCILIZUMAB COMPARED TO TNF-INHIBITORS AND OTHER BDMARDS IN RHEUMATOID ARTHRITIS PATIENTS: DOES LINE OF THERAPY MATTER?

Researchers

Presenter

  • K. Lauper

Principal Investigators

  • L. Kearsley-Fleet

  • R. Davies

  • K. Watson

  • M. Lunt

  • K. Hyrich

Medical Centers

  • Hôpitaux Universitaires de Genève (HUG), Division of Rheumatology, Genève, Switzerland

  • Faculty of Medicine, University of Geneva, Internal Medicine, Genève, Switzerland

  • Centre for Musculoskeletal Research, University of Manchester, Centre for Epidemiology Versus Arthritis, Manchester, United Kingdom

  • The University of Manchester, National Institute for Health Research Manchester Biomedical Research Centre, Manchester, United Kingdom

Locations

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Certolizumab pegol

  • Tocilizumab

  • Adalimumab

  • Infliximab

  • Etanercept

  • CHS-0214

  • Abatacept

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved